Chemours Net Income Growth & History (CC)
Chemours's net income was −$386.0M for fiscal 2025.
View full Chemours company overviewChemours annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$386.0M | −$455.0M | — |
| 2024 | 2024-12-31 | $69.0M | $322.0M | — |
| 2023 | 2023-12-31 | −$253.0M | −$831.0M | — |
| 2022 | 2022-12-31 | $578.0M | −$30.0M | −4.93% |
| 2021 | 2021-12-31 | $608.0M | $389.0M | +177.63% |
| 2020 | 2020-12-31 | $219.0M | $271.0M | — |
| 2019 | 2019-12-31 | −$52.0M | −$1.05B | — |
| 2018 | 2018-12-31 | $995.0M | $249.0M | +33.38% |
| 2017 | 2017-12-31 | $746.0M | $739.0M | +10557.14% |
| 2016 | 2016-12-31 | $7.0M | $97.0M | — |
| 2015 | 2015-12-31 | −$90.0M | −$490.0M | — |
| 2014 | 2014-12-31 | $400.0M | −$23.0M | −5.44% |
| 2013 | 2013-12-31 | $423.0M | — | — |
Chemours quarterly net income
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$274.0M | $106.0M | — |
| Q1 2026 | 2026-03-31 | −$29.0M | −$24.0M | — |
| Q4 2025 | 2025-12-31 | −$47.0M | −$36.0M | — |
| Q3 2025 | 2025-09-30 | $46.0M | $78.0M | — |
| Q2 2025 | 2025-06-30 | −$380.0M | −$440.0M | — |
| Q1 2025 | 2025-03-31 | −$5.0M | −$59.0M | — |
| Q4 2024 | 2024-12-31 | −$11.0M | $7.0M | — |
| Q3 2024 | 2024-09-30 | −$32.0M | −$44.0M | — |
| Q2 2024 | 2024-06-30 | $60.0M | $436.0M | — |
| Q1 2024 | 2024-03-31 | $54.0M | −$91.0M | −62.76% |
| Q4 2023 | 2023-12-31 | −$18.0M | $79.0M | — |
| Q3 2023 | 2023-09-30 | $12.0M | −$228.0M | −95.00% |
| Q2 2023 | 2023-06-30 | −$376.0M | −$577.0M | — |
| Q1 2023 | 2023-03-31 | $145.0M | −$89.0M | −38.03% |
| Q4 2022 | 2022-12-31 | −$97.0M | −$329.0M | — |
| Q3 2022 | 2022-09-30 | $240.0M | $26.0M | +12.15% |
| Q2 2022 | 2022-06-30 | $201.0M | $135.0M | +204.55% |
| Q1 2022 | 2022-03-31 | $234.0M | $138.0M | +143.75% |
| Q4 2021 | 2021-12-31 | $232.0M | $213.0M | +1121.05% |
| Q3 2021 | 2021-09-30 | $214.0M | $138.0M | +181.58% |
| Q2 2021 | 2021-06-30 | $66.0M | $42.0M | +175.00% |
| Q1 2021 | 2021-03-31 | $96.0M | −$4.0M | −4.00% |
| Q4 2020 | 2020-12-31 | $19.0M | $336.0M | — |
| Q3 2020 | 2020-09-30 | $76.0M | $0 | 0.00% |
| Q2 2020 | 2020-06-30 | $24.0M | −$72.0M | −75.00% |
| Q1 2020 | 2020-03-31 | $100.0M | $6.0M | +6.38% |
| Q4 2019 | 2019-12-31 | −$317.0M | −$459.0M | — |
| Q3 2019 | 2019-09-30 | $76.0M | −$199.0M | −72.36% |
| Q2 2019 | 2019-06-30 | $96.0M | −$185.0M | −65.84% |
| Q1 2019 | 2019-03-31 | $94.0M | −$203.0M | −68.35% |
| Q4 2018 | 2018-12-31 | $142.0M | −$86.0M | −37.72% |
| Q3 2018 | 2018-09-30 | $275.0M | $68.0M | +32.85% |
| Q2 2018 | 2018-06-30 | $281.0M | $120.0M | +74.53% |
| Q1 2018 | 2018-03-31 | $297.0M | $147.0M | +98.00% |
| Q4 2017 | 2017-12-31 | $228.0M | $458.0M | — |
| Q3 2017 | 2017-09-30 | $207.0M | $3.0M | +1.47% |
| Q2 2017 | 2017-06-30 | $161.0M | $179.0M | — |
| Q1 2017 | 2017-03-31 | $150.0M | $99.0M | +194.12% |
| Q4 2016 | 2016-12-31 | −$230.0M | −$144.0M | — |
| Q3 2016 | 2016-09-30 | $204.0M | $233.0M | — |
| Q2 2016 | 2016-06-30 | −$18.0M | $0 | — |
| Q1 2016 | 2016-03-31 | $51.0M | $8.0M | +18.60% |
| Q4 2015 | 2015-12-31 | −$86.0M | −$165.0M | — |
| Q3 2015 | 2015-09-30 | −$29.0M | −$136.0M | — |
| Q2 2015 | 2015-06-30 | −$18.0M | −$134.0M | — |
| Q1 2015 | 2015-03-31 | $43.0M | −$55.0M | −56.12% |
| Q4 2014 | 2014-12-31 | $79.0M | — | — |
| Q3 2014 | 2014-09-30 | $107.0M | — | — |
| Q2 2014 | 2014-06-30 | $116.0M | — | — |
| Q1 2014 | 2014-03-31 | $98.0M | — | — |
Chemours net income trends
Over the last five fiscal years, Chemours's net income decreased from $219.0M to −$386.0M, a change of −$605.0M. The latest reported quarter, Q2 2026, shows −$274.0M.
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Chemours source filings ↗Community posts
Chemours, DuPont and Corteva agree to a $455 million PFAS settlement
Chemours ($CC), DuPont ($DD) and Corteva ($CTVA) reached an agreement to resolve PFAS-related claims brought by North Carolina and 11 local government entities. The settlement provides for $455 million in nominal payments over 15 years. Che ...